OncoMatch/Clinical Trials/NCT05832827

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Is NCT05832827 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including MK-3475 and Lenvatinib for untreated advanced or recurrent thymic carcinomas.

Phase 2RecruitingNational Cancer Center, JapanNCT05832827Data as of May 2026

Treatment: MK-3475 · Lenvatinib · Carboplatin · Paclitaxel — A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Allowed: CD5 overexpression

preferred to be positive for CD5 or c-KIT by immunohistochemical staining

Allowed: KIT overexpression

preferred to be positive for CD5 or c-KIT by immunohistochemical staining

Disease stage

Required: Stage III, IVA, IVB (Masaoka-Koga)

unresectable advanced thymic carcinoma (equivalent to stage IVa or IVb of Masaoka-Koga classification), metastatic or recurrent ... Or, in the case of stage III Masaoka-Koga classification, patients who are judged to be incapable of radical resection ... Have measurable disease based on RECIST 1.1

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: vegfr inhibitor

Lab requirements

Blood counts

Adequate organ function as defined in the following table (Table 8). Specimens must be collected within 14 days prior to registration.

Kidney function

Adequate organ function as defined in the following table (Table 8). Specimens must be collected within 14 days prior to registration.

Liver function

Adequate organ function as defined in the following table (Table 8). Specimens must be collected within 14 days prior to registration.

Cardiac function

LVEF below institutional normal range (MUGA or ECHO) excluded; ECG QTcF > 480 ms excluded

Have adequate organ function as defined in the following table (Table 8). LVEF below the institutional normal range, as determined by MUGA or ECHO [excluded]. Patients with ECG QT correction interval prolongation or history of such prolongation (patients with QTcF > 480 ms) [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify